CSIMarket
 
Zura Bio Limited  (NASDAQ: ZURA)
Other Ticker:  
 
 
Price: $1.5500 $0.05 3.333%
Day's High: $1.57 Week Perf: 2.65 %
Day's Low: $ 1.49 30 Day Perf: -20.51 %
Volume (M): 177 52 Wk High: $ 6.35
Volume (M$): $ 275 52 Wk Avg: $3.51
Open: $1.55 52 Wk Low: $1.35



 Market Capitalization (Millions $) 135
 Shares Outstanding (Millions) 87
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) 87
 Capital Exp. (TTM) (Millions $) 0

Zura Bio Limited
Zura Bio Limited is a biotechnology company that specializes in the discovery and development of novel therapeutics. They focus on developing innovative treatments for diseases with unmet medical needs, particularly in the areas of oncology and autoimmune disorders. The company utilizes advanced technologies and cutting-edge research methodologies to identify and optimize potential drug candidates. Zura Bio Limited aims to improve patient outcomes and quality of life through its commitment to scientific excellence and the development of safe and effective therapies.


   Company Address: 1489 W. Warm Springs Rd. #110 Henderson 89014 NV
   Company Phone Number: 825-9872   Stock Exchange / Ticker: NASDAQ ZURA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -1.23%    
BIIB   -3.66%    
CHRS        0.85% 
EXEL        4.48% 
GILD        9.01% 
HALO        1.66% 
• View Complete Report
   



Business Update

Zura Bio Advances Immunology Efforts with FDA Submission and Strategic Warrants Exchange,

Published Thu, Nov 14 2024 11:40 PM UTC

In a pivotal move for the clinical-stage immunology field, Zura Bio Limited (Nasdaq: ZURA) has announced the submission of a protocol for a Phase 2 study of tibulizumab to the U.S. Food and Drug Administration (FDA). Tibulizumab is a cutting-edge humanized tetravalent bispecific dual antagonist antibody, which uniquely neutralizes both IL-17A and another yet-to-be-disclosed ...

Business Update

Zura Bio Reports Promising Q2 2024 Developments Amid Promising Clinical Progress for Autoimmune Therapies

Published Tue, Aug 13 2024 3:47 PM UTC

Zura Bio s Strategic Advancements in Immunology: A Comprehensive Overview of Q2 2024 Financial Results and Key Clinical Progressions HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a pioneering clinical-stage immunology company, has revealed its second quarter 2024 financial results, accompanied by significant business highlights that showcase the company s commitment to ...

Business Update

Zura Bio Updates Stakeholders on Successful Warrant Exchange Offer and Consent Solicitation, Strengthening Ca...

Published Sun, Aug 11 2024 5:32 PM UTC

HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a leading clinical-stage immunology company specializing in the development of innovative dual-pathway antibodies for the treatment of autoimmune and inflammatory diseases, has announced the expiration and results of its previously proposed exchange offer (the Exchange Offer) and consent solicitation (the Consent Solicitatio...

Business Update

Zura Bio Successfully Concludes Warrant Exchange Offer and Consent Solicitation

Published Sat, Aug 10 2024 7:40 AM UTC

In a recent announcement, Zura Bio Limited, a clinical-stage immunology company focused on developing innovative dual-pathway antibodies for autoimmune and inflammatory diseases, disclosed the expiration and outcomes of its exchange offer and consent solicitation. These initiatives pertained to the company s outstanding public warrants, which were originally issued during it...

Business Update

Zura Bio Unveils Promising Tibulizumab Data at EULAR 2024, Spotlighting Advancements in Autoimmune and Inflamma...

Published Fri, Jun 14 2024 10:47 AM UTC

HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), an emergent force in the immunology field, has taken a significant stride forward with the release of encouraging data from its Phase 1 study of tibulizumab (ZB-106) at the Annual European Congress of Rheumatology (EULAR) 2024. This clinical-stage company is distinguished by its innovative approach to developing dual-pathway...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com